

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the  
IPC reform  
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 13 JAN 30 Saved answer limit increased  
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:29:02 ON 02 FEB 2006

=> "solid phase"

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND  
command can only be used to look at the index in a file which has an  
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of  
commands which can be used in this file.

=> file caplus biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY  
2.52

SESSION  
2.52

FILE 'CAPLUS' ENTERED AT 14:35:58 ON 02 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:35:58 ON 02 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

=> solid (s) phase

L1 215795 SOLID (S) PHASE

=> "polystyrene latx particle"

L2 0 "POLYSTYRENE LATX PARTICLE"

=> polystyrene

L3 149966 POLYSTYRENE

=> latex

L4 85771 LATEX

=> L3 and L4

L5 8477 L3 AND L4

=> particle

L6 1272932 PARTICLE

=> L5 and L6

L7 5662 L5 AND L6

=> copolymer

L8 636794 COPOLYMER

=> L8 and L4

L9 21732 L8 AND L4

=> L9 and L6

L10 6687 L9 AND L6

=> erythrocyte

L11 240675 ERYTHROCYTE

=> L11 and L1

L12 634 L11 AND L1

=> gelatiin

L13 0 GELATIIN

=> gelatin

L14 87313 GELATIN

=> L14 and L6

L15 7045 L14 AND L6

=> HCV

L16 32326 HCV

=> L16 and L7

L17 2 L16 AND L7

=> L16 and L9

L18 0 L16 AND L9

=> L16 and L10\

L19 0 L16 AND L10\

=> L16 and L10

L20 0 L16 AND L10

=> L16 and L12

L21 1 L16 AND L12

=> L16 and L15

L22 8 L16 AND L15

=> L16 and L1

L23 185 L16 AND L1

=> NS3 and L23

L24 34 NS3 AND L23

=> core and L24

L25 13 CORE AND L24

=> NS4 and L25

L26 8 NS4 AND L25

=> NS5 and L26

L27 6 NS5 AND L26

=> BSA and L27

L28 0 BSA AND L27

=> BSA

L29 26890 BSA

=> L29 and L24

L30 0 L29 AND L24

=> L29 and L23

L31 0 L29 AND L23

=> ovalbumin

L32 26826 OVALBUMIN

=> L32 and L23

L33 0 L32 AND L23

=> hemocyanin

L34 11251 HEMOCYANIN

=> L34 and L23

L35 1 L34 AND L23

=> D L21 IBIB ABS

L21 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:21470 CAPLUS

DOCUMENT NUMBER: 116:21470

TITLE: Synthetic peptide and reagent for analysis of  
HCV (hepatitis C virus) antibodies using the  
same

INVENTOR(S): Hayashi, Nakanobu; Hashimoto, Masakatsu

PATENT ASSIGNEE(S): Shima Kenkyusho Y. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03190898	A2	19910820	JP 1989-329746	19891221
PRIORITY APPLN. INFO.:			JP 1989-329746	19891221

AB A peptide having the common antigen determinant with HCV virus,

i.e. H-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-OH (I), is prepared by the **solid phase** method on Fmoc- or BOC-Leu-bound resin (Fmoc = 9H-fluoren-9-ylmethoxycarbonyl, BOC = Me<sub>3</sub>CO<sub>2</sub>C) using Fmoc-protected amino acids. A reagent for analyzing **HCV** antibodies by the latex agglutination turbidimetry or light scattering photometry comprises (A), a solid reagent (i.e. I immobilized through phys. absorption or chemical through spacers on a solid support such as a microtiter reaction plate, beads, a sheet, a porous membrane, or magnetic latex, more preferably (high-d.) latex particles, immobilized **erythrocyte**, gelatin particles, or immobilized bacteria) and (B) human globulin antibodies (e.g. human IgG or anti-human IgM) labeled with a radioisotope, enzyme, biotin, fluorescent dye, or Eu chelate or (C) a similarly labeled I. I of high purity can be prepared in large quantity at lower cost than the conventional **HCV**-derived antigen and is easily immobilized on the support and the immobilized I shows good reaction with the **HCV** antibodies of **HCV** patients with high sensitivity and specificity.

=> D L35 IBIB ABS

L35 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:37469 CAPLUS

DOCUMENT NUMBER: 118:37469

TITLE: Basic structural immunogenic polypeptides having epitopes for hepatitis C virus, antibodies, polynucleotide sequence, vaccines, and methods

INVENTOR(S): Kotwal, Girish J.; Baroudy, Bahige M.

PATENT ASSIGNEE(S): Gamble, James N., Institute of Medical Research, USA

SOURCE: PCT Int. Appl., 244 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9212992	A2	19920806	WO 1992-US356	19920114
WO 9212992	A3	19930318		
W: AT, AU, BG, BR, CA, CH, CS, DE, ES, FI, GB, HU, JP, KR, LU, NL, PL, RO, SE				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9214597	A1	19920827	AU 1992-14597	19920114
EP 571554	A1	19931201	EP 1992-907699	19920114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
PRIORITY APPLN. INFO.:			US 1991-639809	A 19910114
			WO 1992-US356	A 19920114

AB Basic immunogenic peptides having epitopes for hepatitis C virus (**HCV**) are disclosed which are derived from the structural region of a human **HCV** genome. Preferred peptides are designated FGB1 and FGB2; sequences and characteristics are presented. Antibodies to the peptides, polynucleotide sequences encoding the peptides, vaccines containing the peptides, and immunoassay and nucleic acid hybridization assay methods, among others, are also disclosed. FGB1 and FGB2 were made by **solid-phase** synthesis and used in ELISAs to detect antibodies to **HCV** in blood and semen. DNA encoding FGB1 was cloned in recombinant vaccinia virus.

=> D L17 IBIB ABS 1-2

L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:610563 CAPLUS

DOCUMENT NUMBER: 131:241966

TITLE: Stabilization of hepatitis C virus antigen-sensitized **latex** reagent

INVENTOR(S): Taiheiraku, Yoshihiro; Ifuku, Yasuo; Miyoshi, Kinya;  
Washisu, Masayoshi  
PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11258241	A2	19990924	JP 1998-56573	19980309
PRIORITY APPLN. INFO.:			JP 1998-56573	19980309

AB **Latex particles** sensitized with antigen or antibody is freeze-dried for stable long-term storage. Dispersing agent, stabilizer, carbohydrate, surfactant and antioxidant are added for stabilization of the immunoassay reagent. A test kit comprising such **latex particles** sensitized with hepatitis C virus antigen (especially C25 antigen) is provided for detecting **HCV**-specific antibody in blood plasma or serum samples.

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:253258 CAPLUS  
DOCUMENT NUMBER: 118:253258  
TITLE: Immunoassay for non-A non-B hepatitis using peptide epitopes of the capsid protein of hepatitis C virus  
INVENTOR(S): Leahy, David C.; Todd, John A.; Jolley, Michael E.  
PATENT ASSIGNEE(S): Baxter Diagnostics Inc., USA  
SOURCE: PCT Int. Appl., 66 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222571	A1	19921223	WO 1992-US3635	19920429
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2087974	AA	19921214	CA 1992-2087974	19920429
AU 9219720	A1	19930112	AU 1992-19720	19920429
AU 648912	B2	19940505		
EP 544861	A1	19930609	EP 1992-911917	19920429
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 06500796	T2	19940127	JP 1992-511153	19920429
JP 3350729	B2	20021125		
PRIORITY APPLN. INFO.:			US 1991-714471	A 19910613
			US 1991-718052	A 19910620
			WO 1992-US3635	A 19920429

AB The title assay uses synthetic peptides comprising the first 38 amino acids of the capsid region containing  $\geq 2$  immunodominant epitopes. The assay detects antibodies in the blood sera of patients infected with hepatitis C virus (**HCV**). Of particular efficacy is a competitive inhibition assay which incorporates in the liquid phase an inhibitor consisting of a peptide containing only 1 of the immunodominant capsid epitopes, which is capable of inhibiting binding of antibodies to all target epitopes present on the solid substrate. Peptide fragments of **HCV** capsid protein and derivs. of these peptides were coated onto paramagnetic **polystyrene** microparticles and tested against human **HCV** antiserum or plasma in a fluorescence enzyme immunoassay to identify immunodominant epitopes.

=> D L26 IBIB ABS 1-6

L26 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1130461 CAPLUS

DOCUMENT NUMBER: 143:385141  
 TITLE: Recombinant antigens (DS-HCV-antigens) for assay of antibodies to hepatitis C virus  
 INVENTOR(S): Burkov, A. N.; Obryadina, A. P.; Ulanova, T. I.; Gladysheva, M. V.  
 PATENT ASSIGNEE(S): Obshchestvo Ogranichennoi Otvetstvennost'yu Nauchno-Proizvodstvennoe Ob'edinenie "Diagnostichekieskie Sistemy", Russia  
 SOURCE: Russ., 15 pp.  
 CODEN: RUXXE7  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2262704	C1	20051020	RU 2004-129264	20041006
PRIORITY APPLN. INFO.:			RU 2004-129264	20041006

AB The disclosed invention proposes a set of recombinant antigens obtained on the basis of amino acid sequences of the most immunoreactive epitopes of hepatitis C virus proteins of different virus genotypes immobilized on surface of a **solid-phase** carrier. This set of recombinant antigens is used to develop an assay of antibodies raised against hepatitis C virus which is of higher sensitivity and specificity.

L26 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:633152 CAPLUS  
 DOCUMENT NUMBER: 141:156083  
 TITLE: Simultaneous detection of **HCV** antigen and anti-**HCV** antibodies in combination assay or sole antibody assay  
 INVENTOR(S): Shah, Dinesh O.; Cheng, Yu; Stewart, James L.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152070	A1	20040805	US 2003-357816	20030204
CA 2515084	AA	20040819	CA 2004-2515084	20040203
WO 2004070387	A1	20040819	WO 2004-US3076	20040203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1590671	A1	20051102	EP 2004-707764	20040203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2003-357816	A 20030204
			WO 2004-US3076	W 20040203

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Such methods may be carried out in the presence of a diluent comprising a reductant or lacking a reductant. Furthermore, the performance of such methods may be maximized by altering such variables as the nature of the antigen coated on the **solid phase**, temperature application and time. The **HCV** antigens are **core** antigen, **NS3**, **NS4**, **NS5** and fragments. The method comprises formation of antigen-antibody complexes, addition of chemiluminescent compound-labeled antibody to bind the antigen-antibody

complexes, and measuring the chemiluminescent signal.

L26 · ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:633162 CAPLUS  
DOCUMENT NUMBER: 139:178676  
TITLE: Methods for the simultaneous detection of **hcv**  
antigens and **hcv** antibodies  
INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A.  
Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas  
P.; Desai, Suresh; Stewart, James L.  
PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S.  
Ser. No. 891,983.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:  
US 2001-891983 A2 20010626  
US 2002-173480 A 20020617  
WO 2002-US19958 W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L26 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:509788 CAPLUS  
DOCUMENT NUMBER: 139:67449  
TITLE: Comparative study of peptide antigens and polymer  
surface interactions. The influence on sensitivity and  
specificity in serodiagnosis of **HCV** and HIV  
AUTHOR(S): Burov, Sergey; Leko, Maria; Glinskaya, Oxana;  
Shkarubskaya, Zoya; Kharina, Maria; Dorosh, Marina;  
Lisok, Tamara; Mobarhan, Asadi  
CORPORATE SOURCE: Institute of Macromolecular Compounds, Academy of  
Sciences, St.-Petersburg, Russia  
SOURCE: Peptides 2000, Proceedings of the European Peptide  
Symposium, 26th, Montpellier, France, Sept. 10-15,  
2000 (2001), Meeting Date 2000, 865-866. Editor(s):  
Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK:  
Paris, Fr.

DOCUMENT TYPE: Conference  
 LANGUAGE: English

AB The determination of specific antibodies against distinct antigenic proteins of a given pathogen is the most commonly used diagnostic tool for the detection of viral infections. Although a large number of the established test systems still use natural antigens from different sources, synthetic peptides, representing the specific antigenic determinants possess the significant advantages. However, the interaction of peptides with the polymer surface may have appreciable influence on the efficiency of their application in ELISA test systems. Apart from induced conformational changes there are significant difference in attachment of polypeptides to the **solid phase** and possible competition for the correspondent binding sites. Thus, quant. control of the antigenic determinants adsorption process may represent a useful tool for the enhancement of ELISA diagnostic system sensitivity.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:23040 CAPLUS

DOCUMENT NUMBER: 138:88633

TITLE: Methods for the simultaneous detection of **HCV** antigens and **HCV** antibodies

INVENTOR(S): Shah, Dinesh O.; Dawson, George A.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2003108858	A1	20030612	US 2001-891983	20010626
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
CA 2450710	AA	20030109	CA 2002-2450710	20020624
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
PRIORITY APPLN. INFO.:			US 2001-891983	A 20010626
			US 2002-173480	A 20020617
			WO 2002-US19958	W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply.

L26 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:298250 CAPLUS

DOCUMENT NUMBER: 131:127333

TITLE: Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric polypeptide for diagnosis of **HCV** infection

AUTHOR(S): Chien, David Y.; Arcangel, Phillip; Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark; Nguyen,

CORPORATE SOURCE: Steve; George-Nascimento, Carlos; Gyenes, Alexander;  
 SOURCE: Kuo, George; Valenzuela, Pablo  
 Chiron Corporation, Emeryville, CA, 94507, USA  
 Journal of Clinical Microbiology (1999), 37(5),  
 1393-1397  
 CODEN: JCMIDW; ISSN: 0095-1137  
 PUBLISHER: American Society for Microbiology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The genome of hepatitis C virus (HCV) consists of seven functional regions: the **core**, E1, E2/NS1, NS2, **NS3**, **NS4**, and NS5 regions. The U.S. Food and Drug Administration-licensed 2.0G immunoassay for the detection of anti-HCV uses proteins from the **core**, **NS3**, and **NS4** regions. The 3.0G ELISA includes the protein from the NS5 region. The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different genotype samples has been demonstrated previously. In this study we have attempted to improve the sensitivity of the anti-HCV assay by developing a single multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of the major immunodominant epitopes from the seven functional regions of the HCV genome. A nucleic acid sequence consisting of proteins from the viral **core**, E1, E2, **NS3**, **NS4**, and NS5 regions and different subtype-specific regions of the **NS4** region was constructed, cloned, and expressed in yeast. The epitopes present on this antigen can be detected by epitope-specific monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6 protein competed with 83 to 96% of genotype-specific antibodies from HCV genotype-specific peptides. This recombinant antigen was subsequently used to design an anti-HCV chemiluminescent immunoassay. We designed our assay using a monoclonal anti-human IgG antibody bound to the **solid phase**. Because MEFA-6 is fused with human superoxide dismutase (h-SOD), we used an anti-human superoxide dismutase, di-Me acridinium ester-labeled monoclonal antibody for detection. Our results indicate that MEFA-6 exposes all of the major immunogenic epitopes. Its excellent sensitivity and specificity for the detection of clin. seroconversion are demonstrated by this assay.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D L27 IBIB ABS 1-6

L27 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1130461 CAPLUS  
 DOCUMENT NUMBER: 143:385141  
 TITLE: Recombinant antigens (DS-HCV-antigens) for assay of antibodies to hepatitis C virus  
 INVENTOR(S): Burkov, A. N.; Obryadina, A. P.; Ulanova, T. I.; Gladysheva, M. V.  
 PATENT ASSIGNEE(S): Obshchestvo Ogranichennoi Otvetstvennost'yu Nauchno-Proizvodstvennoe Ob'edinenie "Diagnostichekieskie Sistemy", Russia  
 SOURCE: Russ., 15 pp.  
 CODEN: RUXXE7  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2262704	C1	20051020	RU 2004-129264	20041006
PRIORITY APPLN. INFO.:			RU 2004-129264	20041006

AB The disclosed invention proposes a set of recombinant antigens obtained on the basis of amino acid sequences of the most immunoreactive epitopes of hepatitis C virus proteins of different virus genotypes immobilized on surface of a **solid-phase** carrier. This set of recombinant antigens is used to develop an assay of antibodies raised

against hepatitis C virus which is of higher sensitivity and specificity.

L27 . ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:633152 CAPLUS  
DOCUMENT NUMBER: 141:156083  
TITLE: Simultaneous detection of **HCV** antigen and  
anti-**HCV** antibodies in combination assay or  
sole antibody assay  
INVENTOR(S): Shah, Dinesh O.; Cheng, Yu; Stewart, James L.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 15 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152070	A1	20040805	US 2003-357816	20030204
CA 2515084	AA	20040819	CA 2004-2515084	20040203
WO 2004070387	A1	20040819	WO 2004-US3076	20040203
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1590671	A1	20051102	EP 2004-707764	20040203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2003-357816 A 20030204 WO 2004-US3076 W 20040203	

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (**HCV**) antigens as well as antibodies produced in response to **HCV** antigens. Such methods may be carried out in the presence of a diluent comprising a reductant or lacking a reductant. Furthermore, the performance of such methods may be maximized by altering such variables as the nature of the antigen coated on the **solid phase**, temperature application and time. The **HCV** antigens are **core** antigen, **NS3**, **NS4**, **NS5** and fragments. The method comprises formation of antigen-antibody complexes, addition of chemiluminescent compound-labeled antibody to bind the antigen-antibody complexes, and measuring the chemiluminescent signal.

L27 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:633162 CAPLUS  
DOCUMENT NUMBER: 139:178676  
TITLE: Methods for the simultaneous detection of **hcv** antigens and **hcv** antibodies  
INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.  
PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626

CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:

US 2001-891983	A2	20010626
US 2002-173480	A	20020617
WO 2002-US19958	W	20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L27 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:23040 CAPLUS  
DOCUMENT NUMBER: 138:88633  
TITLE: Methods for the simultaneous detection of HCV antigens and HCV antibodies  
INVENTOR(S): Shah, Dinesh O.; Dawson, George A.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.  
PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: PCT Int. Appl., 92 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2003108858	A1	20030612	US 2001-891983	20010626
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
CA 2450710	AA	20030109	CA 2002-2450710	20020624
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
PRIORITY APPLN. INFO.:				
			US 2001-891983	A 20010626
			US 2002-173480	A 20020617
			WO 2002-US19958	W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety

of the blood supply.

L27 · ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:298250 CAPLUS

DOCUMENT NUMBER: 131:127333

TITLE: Use of a novel hepatitis C virus (HCV)  
major-epitope chimeric polypeptide for diagnosis of  
HCV infection

AUTHOR(S): Chien, David Y.; Arcangel, Phillip; Medina-Selby,  
Angelica; Coit, Doris; Baumeister, Mark; Nguyen,  
Steve; George-Nascimento, Carlos; Gyenes, Alexander;  
Kuo, George; Valenzuela, Pablo

CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94507, USA

SOURCE: Journal of Clinical Microbiology (1999), 37(5),  
1393-1397

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The genome of hepatitis C virus (HCV) consists of seven  
functional regions: the **core**, E1, E2/NS1, NS2, **NS3**,  
**NS4**, and **NS5** regions. The U.S. Food and Drug  
Administration-licensed 2.0G immunoassay for the detection of anti-  
HCV uses proteins from the **core**, **NS3**, and  
**NS4** regions. The 3.0G ELISA includes the protein from the  
**NS5** region. The necessity of detecting antibodies to viral  
envelope proteins (E1 and E2) and to different genotype samples has been  
demonstrated previously. In this study we have attempted to improve the  
sensitivity of the anti-HCV assay by developing a single  
multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of  
the major immunodominant epitopes from the seven functional regions of the  
HCV genome. A nucleic acid sequence consisting of proteins from  
the viral **core**, E1, E2, **NS3**, **NS4**, and  
**NS5** regions and different subtype-specific regions of the  
**NS4** region was constructed, cloned, and expressed in yeast. The  
epitopes present on this antigen can be detected by epitope-specific  
monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6  
protein competed with 83 to 96% of genotype-specific antibodies from  
HCV genotype-specific peptides. This recombinant antigen was  
subsequently used to design an anti-HCV chemiluminescent  
immunoassay. We designed our assay using a monoclonal anti-human IgG  
antibody bound to the **solid phase**. Because MEFA-6 is  
fused with human superoxide dismutase (h-SOD), we used an anti-human  
superoxide dismutase, di-Me acridinium ester-labeled monoclonal antibody  
for detection. Our results indicate that MEFA-6 exposes all of the major  
immunogenic epitopes. Its excellent sensitivity and specificity for the  
detection of clin. seroconversion are demonstrated by this assay.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1999:241608 BIOSIS

DOCUMENT NUMBER: PREV199900241608

TITLE: Use of a novel hepatitis C virus (HCV)  
major-epitope chimeric polypeptide for diagnosis of  
HCV infection.

AUTHOR(S): Chien, David Y. [Reprint author]; Arcangel, Phillip;  
Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark;  
Nguyen, Steve; George-Nascimento, Carlos; Gyenes,  
Alexander; Kuo, George; Valenzuela, Pablo

CORPORATE SOURCE: Life Science Center 4.302, Chiron Corporation, 4560 Horton  
St., Emeryville, CA, 94507, USA

SOURCE: Journal of Clinical Microbiology, (May, 1999) Vol. 37, No.  
5, pp. 1393-1397. print.

CODEN: JCMIDW. ISSN: 0095-1137.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 17 Jun 1999

Last Updated on STN: 17 Jun 1999

AB The genome of hepatitis C virus (HCV) consists of seven functional regions: the **core**, E1, E2/NS1, NS2, **NS3**, **NS4**, and **NS5** regions. The U.S. Food and Drug Administration-licensed 2.0G immunoassay for the detection of anti-HCV uses proteins from the **core**, **NS3**, and **NS4** regions (McHutchinson et al., Hepatology 15:19-25, 1992). The 3.0G enzyme-linked immunosorbent assay includes the protein from the **NS5** region (Uyttendaele et al., Vox Sang. 66:122-129, 1994). The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different genotype samples has been demonstrated previously (Chien et al., Lancet 342:933, 1993; Lok et al., Hepatology 18:497-502, 1993). In this study we have attempted to improve the sensitivity of the anti-HCV assay by developing a single multiple-epitope fusion antigen (MEFA; MEFA-6) which incorporates all of the major immunodominant epitopes from the seven functional regions of the HCV genome. A nucleic acid sequence consisting of proteins from the viral **core**, E1, E2, **NS3**, **NS4**, and **NS5** regions and different subtype-specific regions of the **NS4** region was constructed, cloned, and expressed in yeast. The epitopes present on this antigen can be detected by epitope-specific monoclonal and polyclonal antibodies. In a competition assay, the MEFA-6 protein competed with 83 to 96% of genotype-specific antibodies from HCV genotype-specific peptides. This recombinant antigen was subsequently used to design an anti-HCV chemiluminescent immunoassay. We designed our assay using a monoclonal anti-human immunoglobulin G antibody bound to the **solid phase**. Because MEFA-6 is fused with human superoxide dismutase (h-SOD), we used an anti-human superoxide dismutase, dimethyl acridinium ester-labeled monoclonal antibody for detection. Our results indicate that MEFA-6 exposes all of the major immunogenic epitopes. Its excellent sensitivity and specificity for the detection of clinical seroconversion are demonstrated by this assay.

=> D L22 IBIB ABS 1-8

L22 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:644976 CAPLUS  
DOCUMENT NUMBER: 137:165835  
TITLE: Virus nucleic acid isolation via surface binding and surfactant release and PCR amplification  
INVENTOR(S): Murata, Mitsuhiro; Fan, Ke-Chun; Higata, Mikio; Sato, Koei; Yamaguchi, Teruhide  
PATENT ASSIGNEE(S): JSR Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2002238565	A2	20020827	JP 2001-35066	20010213
PRIORITY APPLN. INFO.:			JP 2001-35066	20010213

AB This invention provides a method of isolation of nucleic acid from virus by binding of virus to a water insol. support and separation of nucleic acid using a surfactant and amplification via PCR. A glass or magnetic **particle** support containing a virus-binding substance such as antibodies to virus surface antigen, lectin, or glycoconjugate, are used. An anionic surfactant or a steroid-containing surfactant is used in combination with albumin or **gelatin**. Isolation of HBV using an anti-HBs antibody immobilized glass beads, deoxycholic acid, and BSA, and isolation of HCV using a Ricin A chain immobilized magnetic **particles**, and sodium N-lauroyl sarcosinate, and RT-PCR amplification are described.

L22 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:498585 CAPLUS  
DOCUMENT NUMBER: 131:167375

TITLE: Superoxide dismutase fusion protein-binding reagent as absorbent to remove nonspecific reaction in immunoassay  
 INVENTOR(S): Kawado, Katsuhito; Nakamura, Masato  
 PATENT ASSIGNEE(S): Fujirebio, Inc., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11218534	A2	19990810	JP 1998-32372	19980130
JP 3520757	B2	20040419		

PRIORITY APPLN. INFO.: JP 1998-32372 19980130

OTHER SOURCE(S): MARPAT 131:167375

AB Aminocarboxylic acids, e.g.  $\epsilon$ -aminocaproic acid, p-(aminomethyl)cyclohexanecarboxylic acid and lysine, are provided as absorbent for immunoassay to reduce nonspecific binding of superoxide dismutase-antigen fusion protein. Thus, fusion protein comprising superoxide dismutase and hepatitis C virus core antigen C200 protein was prepared by mol. cloning and coated on **gelatin particles** for immunoassay of anti-HCV antibody in serum sample in the presence of above mentioned aminocarboxylic acids.

L22 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:554170 CAPLUS

DOCUMENT NUMBER: 129:310488

TITLE: Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease

AUTHOR(S): Da Silva, C. M. F.; David, F. L.; Muscara, M. N.; Sousa, S. S.; Ferraz, J. G. P.; De Nucci, G.; Polimeno, N. C.; Pedrazzoli, J., Jr.

CORPORATE SOURCE: Clinical Pharmacology Unit, Sao Francisco University Medical School, Braganca Paulista, 218 12900-000, Brazil

SOURCE: British Journal of Clinical Pharmacology (1998), 46(2), 176-180

CODEN: BCPHBM; ISSN: 0306-5251

PUBLISHER: Blackwell Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Our objective was to evaluate plasma hydroxy-metronidazole/metronidazole ratio as a dynamic liver function test in HCV-infected individuals with/without liver disease, in the absence of liver cirrhosis. Metronidazole was administered i.v. in healthy volunteers, asymptomatic anti-HCV-pos. blood donors, and in chronic hepatitis C patients. Serol. to HCV was determined by a second generation assay and confirmed by **gelatin particle** agglutination test using recombinant antigens C22-3 and C200. Plasma concentration of metronidazole and hydroxy-metronidazole was measured by high performance liquid chromatog. in samples collected 5, 10, 20 and 30 min following the end of metronidazole infusion. Chronic hepatitis C patients had abnormal liver enzymes, while healthy volunteers and anti-HCV-pos. blood donors had normal liver biochem. tests. Plasma metronidazole concentration was similar in all groups studied. Plasma hydroxy-metronidazole/metronidazole ratio was significantly reduced in HCV-infected subjects, an effect observed 10 min after the end of drug infusion. Metronidazole clearance is impaired in anti-HCV-pos. blood donors and chronic hepatitis C patients, indicating that HCV is capable of affecting liver function at early stages of the disease. The metronidazole clearance test can detect impaired liver function in HCV-infected individuals even in the absence of liver cirrhosis.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1994:625871 CAPLUS  
 DOCUMENT NUMBER: 121:225871  
 TITLE: Immunoassay with solid support-immobilized and magnetic **particle**-immobilized same antigen  
 INVENTOR(S): Kaneko, Yasunobu  
 PATENT ASSIGNEE(S): Olympus Optical Co, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06186231	A2	19940708	JP 1992-341808	19921222
PRIORITY APPLN. INFO.:			JP 1992-341808	19921222

AB The title method uses an immobilized antigen on the inner wall of a reaction chamber and an immobilized same antigen on a magnetic carrier **particle** (e.g. **gelatin**). Thus, for determination of anti-hepatitis C virus (**HCV**) antibody, **HCV** core antigen was immobilized on the well bottom of a plate and sep. on **gelatin particle**. Use of the magnetic **particle** -immobilized **HCV** core antigen exhibited higher sensitivity than with a magnetic **particle**-immobilized anti-human IgG antibody.

ACCESSION NUMBER: 1992:21470 CAPLUS  
 DOCUMENT NUMBER: 116:21470  
 TITLE: Synthetic peptide and reagent for analysis of **HCV** (hepatitis C virus) antibodies using the same  
 INVENTOR(S): Hayashi, Nakanobu; Hashimoto, Masakatsu  
 PATENT ASSIGNEE(S): Shima Kenkyusho Y. K., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03190898	A2	19910820	JP 1989-329746	19891221
PRIORITY APPLN. INFO.:			JP 1989-329746	19891221

AB A peptide having the common antigen determinant with **HCV** virus, i.e. H-Ile-Ile-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Met-Leu-Ala-Glu-Gln-Phe-Lys-Gln-Lys-Ala-Leu-Gly-Leu-OH (I), is prepared by the solid phase method on Fmoc- or BOC-Leu-bound resin (Fmoc = 9H-fluoren-9-ylmethoxycarbonyl, BOC = Me3CO2C) using Fmoc-protected amino acids. A reagent for analyzing **HCV** antibodies by the latex agglutination turbidimetry or light scattering photometry comprises (A), a solid reagent (i.e. I immobilized through phys. absorption or chemical through spacers on a solid support such as a microtiter reaction plate, beads, a sheet, a porous membrane, or magnetic latex, more preferably (high-d.) latex **particles**, immobilized erythrocyte, **gelatin particles**, or immobilized bacteria) and (B) human globulin antibodies (e.g. human IgG or anti-human IgM) labeled with a radioisotope, enzyme, biotin, fluorescent dye, or Eu chelate or (C) a similarly labeled I. I of high purity can be prepared in large quantity at lower cost than the conventional **HCV** -derived antigen and is easily immobilized on the support and the immobilized I shows good reaction with the **HCV** antibodies of **HCV** patients with high sensitivity and specificity.

ACCESSION NUMBER: 2003:30922 BIOSIS  
 DOCUMENT NUMBER: PREV200300030922

TITLE: Transfusion transmissible infections (TTI) markers development over an eight-year period in a hospital blood bank in Argentina.  
AUTHOR(S): Remesar, M. [Reprint Author]; Oknaian, S. [Reprint Author]; del Pozo, A. [Reprint Author]  
CORPORATE SOURCE: Servicio de Hemoterapia, Hospital de Pediatria Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina  
SOURCE: Vox Sanguinis, (August 2002) Vol. 83, No. Supplement 2, pp. 195-196. print.  
Meeting Info.: 27th Congress of the International Society of Blood Transfusion held in conjunction with Canadian Society of Transfusion Medicine. Vancouver, British Colombia, Canada. August 24-29, 2002. International Society of Blood Transfusion; Canadian Society of Transfusion Medicine.  
ISSN: 0042-9007 (ISSN print).  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 8 Jan 2003  
Last Updated on STN: 8 Jan 2003

L22 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1998:401913 BIOSIS  
DOCUMENT NUMBER: PREV199800401913  
TITLE: Plasma hydroxy metronidazole/metronidazole ration in anti-HCV carriers with and without apparent liver disease.  
AUTHOR(S): da Silva, C. M. F.; David, F. L.; Muscara, M. N.; Sousa, S. S.; Ferraz, J. G. P.; De Nucci, G.; Polimeno, N. C.; Pedrazzoli, J., Jr. [Reprint author]  
CORPORATE SOURCE: Clin. Pharmacol. Unit, Sao Francisco Univ. Med. Sch., Av. Sao Francisco de Assis, 218 12900-000, Braganca Paulista, SP, Brazil  
SOURCE: British Journal of Clinical Pharmacology, (Aug., 1998) Vol. 46, No. 2, pp. 176-180. print.  
CODEN: BCPHBM. ISSN: 0306-5251.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Sep 1998  
Last Updated on STN: 21 Sep 1998

AB Aims: To evaluate plasma hydroxy-metronidazole/metronidazole ratio as a dynamic liver function test in HCV-infected individuals with/without liver disease, in the absence of liver cirrhosis. Methods: Metronidazole was administered intravenously in healthy volunteers, asymptomatic anti-HCV-positive blood donors, and in chronic hepatitis C patients. Serology to HCV was determined by a second generation assay and confirmed by **gelatin particle** agglutination test using recombinant antigens C22-3 and C200. Plasma concentration of metronidazole and hydroxy-metronidazole was measured by high performance liquid chromatography in samples collected 5, 10, 20 and 30 min following the end of metronidazole infusion. Results: Chronic hepatitis C patients had abnormal liver enzymes, while healthy volunteers and anti-HCV-positive blood donors had normal liver biochemistry tests. Plasma metronidazole concentration was similar in all groups studied. Plasma hydroxy-metronidazole/metronidazole ratio was significantly reduced in HCV-infected subjects, an effect observed 10 min after the end of drug infusion. Conclusions: Metronidazole clearance is impaired in anti-HCV-positive blood donors and chronic hepatitis C patients, indicating that HCV is capable of affecting liver function at early stages of the disease. The metronidazole clearance test can detect impaired liver function in HCV-infected individuals even in the absence of liver cirrhosis.

L22 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1996:395811 BIOSIS  
DOCUMENT NUMBER: PREV199699118167  
TITLE: Characterization of the low titer group of anti-HCV positive donors determined by **gelatin**

particle agglutination test.

AUTHOR(S): Awakihara, Shuji; Naoki, Kyoko; Miyahara, Masayuki; Sato, Hiromasa  
CORPORATE SOURCE: Japanese Red Cross Okayama Blood Center, Okayama, Japan  
SOURCE: Vox Sanguinis, (1996) Vol. 70, No. SUPPL. 2, pp. 147.  
Meeting Info.: 24th Congress of the International Society of Blood Transfusion. Makuhari Messe, Japan. March 31-April 5, 1996.  
CODEN: VOSAAD. ISSN: 0042-9007.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Sep 1996  
Last Updated on STN: 3 Sep 1996

=> D L24 IBIB TI 1-34

L24 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1130461 CAPLUS  
DOCUMENT NUMBER: 143:385141  
TITLE: Recombinant antigens (DS-HCV-antigens) for assay of antibodies to hepatitis C virus  
INVENTOR(S): Burkov, A. N.; Obryadina, A. P.; Ulanova, T. I.; Gladysheva, M. V.  
PATENT ASSIGNEE(S): Obshchestvo Ogranichennoi Otvetstvennost'yu Nauchno-Proizvodstvennoe Ob'edinenie "Diagnosticheskie Sistemy", Russia  
SOURCE: Russ., 15 pp.  
CODEN: RUXXE7  
DOCUMENT TYPE: Patent  
LANGUAGE: Russian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2262704	C1	20051020	RU 2004-129264	20041006
PRIORITY APPLN. INFO.:			RU 2004-129264	20041006
TI	Recombinant antigens (DS-HCV-antigens) for assay of antibodies to hepatitis C virus			

L24 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:633152 CAPLUS  
DOCUMENT NUMBER: 141:156083  
TITLE: Simultaneous detection of HCV antigen and anti-HCV antibodies in combination assay or sole antibody assay  
INVENTOR(S): Shah, Dinesh O.; Cheng, Yu; Stewart, James L.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 15 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152070	A1	20040805	US 2003-357816	20030204
CA 2515084	AA	20040819	CA 2004-2515084	20040203
WO 2004070387	A1	20040819	WO 2004-US3076	20040203
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,			

MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG  
EP 1590671 A1 20051102 EP 2004-707764 20040203  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
PRIORITY APPLN. INFO.: US 2003-357816 A 20030204  
WO 2004-US3076 W 20040203

TI Simultaneous detection of **HCV** antigen and anti-**HCV**  
antibodies in combination assay or sole antibody assay

L24 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:912843 CAPLUS

DOCUMENT NUMBER: 139:381756

TITLE: Preparation of peptides as **NS3**-serine  
protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil;  
Lovey, Raymond G.; Jao, Edwin; Bennett, Frank;  
McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.;  
Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-tsung; Zhu,  
Zhaoning; Njoroge, F. George; Arasappan, Ashok;  
Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.;  
Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto,  
Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey;  
Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura,  
Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 629 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003216325	A1	20031120	US 2001-908955	20010719
US 2004254117	A9	20041216		
CN 1498224	A	20040519	CN 2001-813111	20010719
ZA 2002010312	A	20040329	ZA 2002-10312	20021219
PRIORITY APPLN. INFO.:			US 2000-220108P	P 20000721

OTHER SOURCE(S): MARPAT 139:381756

TI Preparation of peptides as **NS3**-serine protease inhibitors of  
hepatitis C virus

L24 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:634705 CAPLUS

TITLE: **Solid phase** parallel synthesis of  
alpha-ketoamide inhibitors of **NS3**-4A  
**HCV** Protease

AUTHOR(S): Court, John J.; Cottrell, Kevin C.; Harbeson, Scott  
L.; Pitlik, Janos

CORPORATE SOURCE: Department of Medicinal Chemistry, Vertex  
Pharmaceuticals Inc, Cambridge, MA, 02139, USA

SOURCE: Abstracts of Papers, 226th ACS National Meeting, New  
York, NY, United States, September 7-11, 2003 (2003),  
MEDI-097. American Chemical Society: Washington, D.  
C.

CODEN: 69EKY9

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

TI **Solid phase** parallel synthesis of alpha-ketoamide  
inhibitors of **NS3**-4A **HCV** Protease

L24 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:633162 CAPLUS

DOCUMENT NUMBER: 139:178676

TITLE: Methods for the simultaneous detection of **hcv**  
antigens and **hcv** antibodies

INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A.

PATENT ASSIGNEE(S): Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.  
 SOURCE: Abbott Laboratories, USA  
 U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:  
 US 2001-891983 A2 20010626  
 US 2002-173480 A 20020617  
 WO 2002-US19958 W 20020624

TI Methods for the simultaneous detection of **hcv** antigens and **hcv** antibodies

L24 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:509788 CAPLUS

DOCUMENT NUMBER: 139:67449

TITLE: Comparative study of peptide antigens and polymer surface interactions. The influence on sensitivity and specificity in serodiagnosis of **HCV** and HIV

AUTHOR(S): Burov, Sergey; Leko, Maria; Glinskaya, Oxana; Shkarubskaya, Zoya; Kharina, Maria; Dorosh, Marina; Lisok, Tamara; Mobarhan, Asadi

CORPORATE SOURCE: Institute of Macromolecular Compounds, Academy of Sciences, St.-Petersburg, Russia

SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 865-866. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE: Conference

LANGUAGE: English

TI Comparative study of peptide antigens and polymer surface interactions. The influence on sensitivity and specificity in serodiagnosis of **HCV** and HIV

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:393701 CAPLUS

DOCUMENT NUMBER: 139:381715

TITLE: Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length **NS3** (Protease-Helicase/NTPase): a comparative study of different C-terminals

AUTHOR(S): Johansson, Anja; Poliakov, Anton; Akerblom, Eva; Wiklund, Karin; Lindeberg, Gunnar; Winiwarer, Susanne; Danielson, U. Helena; Samuelsson, Bertil;

Hallberg, Anders  
CORPORATE SOURCE: BMC, Department of Medicinal Chemistry, Uppsala  
University, Uppsala, SE-751 23, Swed.  
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(12),  
2551-2568  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 139:381715  
TI Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus  
full-length **NS3** (Protease-Helicase/NTase): a comparative study  
of different C-terminals  
REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:23040 CAPLUS  
DOCUMENT NUMBER: 138:88633  
TITLE: Methods for the simultaneous detection of **HCV**  
antigens and **HCV** antibodies  
INVENTOR(S): Shah, Dinesh O.; Dawson, George A.; Muerhoff, A.  
Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas  
P.; Desai, Suresh; Stewart, James L.  
PATENT ASSIGNEE(S): Abbott Laboratories, USA  
SOURCE: PCT Int. Appl., 92 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, PT, SE, TR				
US 2003108858	A1	20030612	US 2001-891983	20010626
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
CA 2450710	AA	20030109	CA 2002-2450710	20020624
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
PRIORITY APPLN. INFO.:			US 2001-891983	A 20010626
			US 2002-173480	A 20020617
			WO 2002-US19958	W 20020624

TI Methods for the simultaneous detection of **HCV** antigens and  
**HCV** antibodies

L24 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:777963 CAPLUS  
DOCUMENT NUMBER: 137:295254  
TITLE: Preparation of peptide inhibitors of hepatitis C virus  
**NS3** protease  
INVENTOR(S): Colarusso, Stefania; Gardelli, Cristina; Gerlach,  
Benjamin; Harper, Steven; Koch, Uwe; Matassa, Victor  
Giulio; Muraglia, Ester; Narjes, Frank; Ontoria,  
Ontoria Jesus Maria; Petrocchi, Alessia; Ponzi,  
Simona; Stansfield, Ian; Summa, Vincenzo  
PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P.  
Angeletti Spa, Italy; et al.  
SOURCE: PCT Int. Appl., 151 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079234	A1	20021010	WO 2002-EP3435	20020326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2442540	AA	20021010	CA 2002-2442540	20020326
EP 1392721	A1	20040303	EP 2002-757728	20020326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004142876	A1	20040722	US 2004-473443	20040303
PRIORITY APPLN. INFO.:			GB 2001-7924	A 20010329
			WO 2002-EP3435	W 20020326

OTHER SOURCE(S): MARPAT 137:295254

TI Preparation of peptide inhibitors of hepatitis C virus **NS3** protease

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:692477 CAPLUS

DOCUMENT NUMBER: 138:369163

TITLE: Different types of P1 residues in peptide-based inhibitors of hepatitis C virus full-length **NS3** protease

AUTHOR(S): Johansson, Anja; Akerblom, Eva; Lindeberg, Gunnar; Poliakov, Anton; Danielsson, U. Helena; Hallberg, Anders

CORPORATE SOURCE: Department of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, SE-751 23, Swed.

SOURCE: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 549-550. Editor(s): Lebl, Michal; Houghten, Richard A. American Peptide Society: San Diego, Calif.  
CODEN: 69DBAL; ISBN: 0-9715560-0-8

DOCUMENT TYPE: Conference

LANGUAGE: English

TI Different types of P1 residues in peptide-based inhibitors of hepatitis C virus full-length **NS3** protease

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:116966 CAPLUS

DOCUMENT NUMBER: 137:125377

TITLE: Solution and **solid-Phase** synthesis of potent inhibitors of hepatitis C Virus **NS3** proteinase

AUTHOR(S): Beevers, Rebekah; Carr, Maria G.; Jones, Philip S.; Jordan, Steven; Kay, Paul B.; Lazell, Robert C.; Raynham, Tony M.

CORPORATE SOURCE: Department of Chemistry, Roche Discovery Welwyn, Hertfordshire, Welwyn Garden City, AL7 3AY, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 641-643  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 137:125377  
 TI Solution and **solid-Phase** synthesis of potent  
 inhibitors of hepatitis C Virus **NS3** proteinase  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:90007 CAPLUS  
 DOCUMENT NUMBER: 136:151439  
 TITLE: Preparation of novel peptides as **NS3**-serine  
 protease inhibitors of hepatitis C virus  
 INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil;  
 Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.;  
 Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan;  
 Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu,  
 Zhaoning; Arasappan, Ashok; Chen, Kevin X.;  
 Venkatraman, Srikanth; Parekh, Tejal N.; Pinto,  
 Patrick A.; Santhanam, Bama; Njoroge, F. George;  
 Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott  
 Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita;  
 Tamura, Susan Y.  
 PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.  
 SOURCE: PCT Int. Appl., 188 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2410682	AA	20020131	CA 2001-2410682	20010719
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001012666	A	20030610	BR 2001-12666	20010719
JP 2004513881	T2	20040513	JP 2002-514094	20010719
NZ 523781	A	20041029	NZ 2001-523781	20010719
ZA 2002010311	A	20040319	ZA 2002-10311	20021219
NO 2003000271	A	20030318	NO 2003-271	20030120
US 2005176648	A1	20050811	US 2005-89192	20050324
PRIORITY APPLN. INFO.:			US 2000-220107P	P 20000721
			US 2001-909012	A3 20010719
			WO 2001-US22813	W 20010719

OTHER SOURCE(S): MARPAT 136:151439  
 TI Preparation of novel peptides as **NS3**-serine protease inhibitors  
 of hepatitis C virus  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:864881 CAPLUS  
 DOCUMENT NUMBER: 136:4700  
 TITLE: Method for preparing antigen-bound **solid**  
**phase** carrier  
 INVENTOR(S): Sakagami, Naohito; Yamamoto, Katsuhiko  
 PATENT ASSIGNEE(S): Fujirebio, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001330616	A2	20011130	JP 2000-149215	20000522
PRIORITY APPLN. INFO.:			JP 2000-149215	20000522

TI Method for preparing antigen-bound **solid phase** carrier

L24 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:435622 CAPLUS

DOCUMENT NUMBER: 135:195782

TITLE: **Solid-Phase** Synthesis of  
Peptidomimetic Inhibitors for the Hepatitis C Virus  
**NS3** Protease

AUTHOR(S): Poupart, Marc-Andre; Cameron, Dale R.; Chabot,  
Catherine; Ghiro, Elise; Goudreau, Nathalie; Goulet,  
Sylvie; Poirier, Martin; Tsantrizos, Youla S.

CORPORATE SOURCE: Department of Chemistry, Boehringer Ingelheim (Canada)  
Ltd., QC, H7S 2G5, Can.

SOURCE: Journal of Organic Chemistry (2001), 66(14), 4743-4751  
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:195782

TI **Solid-Phase** Synthesis of Peptidomimetic Inhibitors for  
the Hepatitis C Virus **NS3** Protease

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:338559 CAPLUS

DOCUMENT NUMBER: 134:340710

TITLE: Preparation of peptides as **HCV NS3**  
protease inhibitors

INVENTOR(S): Fattori, Daniela; Pessi, Antonello; Ingallinella,  
Paolo; Bianchi, Elisabetta

PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P.  
Angeletti S.p.A., Italy; Nicholls, Kathryn, M.

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032691	A1	20010510	WO 2000-GB4195	20001102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2389543	AA	20010510	CA 2000-2389543	20001102
EP 1230260	A1	20020814	EP 2000-973007	20001102
EP 1230260	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003513891	T2	20030415	JP 2001-535390	20001102

AT 250080	E	20031015	AT 2000-973007	20001102
ES 2204713	T3	20040501	ES 2000-973007	20001102
AU 780100	B2	20050303	AU 2001-11564	20001102
PRIORITY APPLN. INFO.:			GB 1999-25955	A 19991102
			WO 2000-GB4195	W 20001102

OTHER SOURCE(S):           MARPAT 134:340710  
 TI   Preparation of peptides as **HCV NS3** protease inhibitors  
 REFERENCE COUNT:       2       THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
    RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:       2000:97717 CAPLUS  
 DOCUMENT NUMBER:       132:293998  
 TITLE:                   **Solid phase** synthesis of peptide  
                           aldehyde protease inhibitors. Probing the proteolytic  
                           sites of hepatitis C virus polyprotein  
 AUTHOR(S):              Ede, Nicholas J.; Eagle, Susan N.; Wickham, Geoffrey;  
                           Bray, Andrew M.; Warne, Bob; Shoemaker, Kevin;  
                           Rosenberg, Steve  
 CORPORATE SOURCE:       Chiron Technologies Pty. Ltd., Clayton, 3168,  
                           Australia  
 SOURCE:                  Journal of Peptide Science (2000), 6(1), 11-18  
                           CODEN: JPSIEI; ISSN: 1075-2617  
 PUBLISHER:              John Wiley & Sons Ltd.  
 DOCUMENT TYPE:         Journal  
 LANGUAGE:               English  
 OTHER SOURCE(S):       CASREACT 132:293998  
 TI   **Solid phase** synthesis of peptide aldehyde protease  
      inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein  
 REFERENCE COUNT:       18       THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
    RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:       1999:810845 CAPLUS  
 DOCUMENT NUMBER:       132:117137  
 TITLE:                   A loop-mimetic inhibitor of the **HCV-**  
                           **NS3** protease derived from a minibody  
 AUTHOR(S):              Martin, F.; Steinkuhler, C.; Brunetti, M.; Pessi, A.;  
                           Cortese, R.; De Francesco, R.; Sollazzo, M.  
 CORPORATE SOURCE:       Istituto di Ricerche di Biologia Molecolare (IRBM) P.  
                           Angeletti, Rome, 600-00040, Italy  
 SOURCE:                  Protein Engineering (1999), 12(11), 1005-1011  
                           CODEN: PRENE9; ISSN: 0269-2139  
 PUBLISHER:              Oxford University Press  
 DOCUMENT TYPE:         Journal  
 LANGUAGE:               English  
 TI   A loop-mimetic inhibitor of the **HCV-NS3** protease  
      derived from a minibody  
 REFERENCE COUNT:       51       THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
    RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:       1999:691299 CAPLUS  
 DOCUMENT NUMBER:       131:335784  
 TITLE:                   Preparation of recombinant **HCV NS3**  
                           antigen and immobilization of the antigen in the  
                           presence of reducing agent for immunodiagnostic assay  
 INVENTOR(S):            Maertens, Geert; Louwagie, Joost; Bosman, Alfons;  
                           Sablon, Erwin; Zrein, Maan  
 PATENT ASSIGNEE(S):     Innogenetics N.V., Belg.  
 SOURCE:                  PCT Int. Appl., 66 pp.  
                           CODEN: PIXXD2  
 DOCUMENT TYPE:         Patent  
 LANGUAGE:               English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9954735	A1	19991028	WO 1999-EP2547	19990415
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2324970	AA	19991028	CA 1999-2324970	19990415
AU 9938171	A1	19991108	AU 1999-38171	19990415
AU 751362	B2	20020815		
BR 9909678	A	20001219	BR 1999-9678	19990415
TR 200003024	T2	20001221	TR 2000-200003024	19990415
EP 1071955	A1	20010131	EP 1999-920678	19990415
EP 1071955	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002512370	T2	20020423	JP 2000-545027	19990415
TR 200101647	T2	20020621	TR 2001-200101647	19990415
TR 200101648	T2	20020621	TR 2001-200101648	19990415
TR 200202213	T2	20021121	TR 2002-200202213	19990415
AT 278960	E	20041015	AT 1999-920678	19990415
EP 1471074	A2	20041027	EP 2004-103238	19990415
EP 1471074	A3	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
PT 1071955	T	20050228	PT 1999-920678	19990415
ES 2230851	T3	20050501	ES 1999-920678	19990415
ZA 2000005445	A	20030106	ZA 2000-5445	20001005
HK 1036653	A1	20050408	HK 2001-105349	20010731
JP 2005185285	A2	20050714	JP 2005-767	20050105
PRIORITY APPLN. INFO.:			EP 1998-870087	A 19980417
			EP 1999-920678	A3 19990415
			JP 2000-545027	A3 19990415
			WO 1999-EP2547	W 19990415

TI Preparation of recombinant **HCV NS3** antigen and immobilization of the antigen in the presence of reducing agent for immunodiagnostic assay

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:640820 CAPLUS

DOCUMENT NUMBER: 131:257878

TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus **NS3** protease

INVENTOR(S): Tung, Roger D.; Farmer, Luc J.; Bhisetti, Govinda R.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950230	A1	19991007	WO 1999-US7149	19990331
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
AU 9933766 A1 19991018 AU 1999-33766 19990331  
EP 1066247 A1 20010110 EP 1999-915185 19990331  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI  
JP 2002509910 T2 20020402 JP 2000-541139 19990331  
US 6608067 B1 20030819 US 2000-677382 20000929  
US 2004077600 A1 20040422 US 2003-614432 20030707  
PRIORITY APPLN. INFO.: US 1998-80060P A1 19980331  
WO 1999-US7149 W 19990331  
US 2000-677382 A3 20000929

OTHER SOURCE(S): MARPAT 131:257878  
TI Preparation of peptide analogs as inhibitors of serine proteases,  
particularly hepatitis C virus **NS3** protease  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:298250 CAPLUS  
DOCUMENT NUMBER: 131:127333  
TITLE: Use of a novel hepatitis C virus (**HCV**)  
major-epitope chimeric polypeptide for diagnosis of  
**HCV** infection  
AUTHOR(S): Chien, David Y.; Arcangel, Phillip; Medina-Selby,  
Angelica; Coit, Doris; Baumeister, Mark; Nguyen,  
Steve; George-Nascimento, Carlos; Gyenes, Alexander;  
Kuo, George; Valenzuela, Pablo  
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, 94507, USA  
SOURCE: Journal of Clinical Microbiology (1999), 37(5),  
1393-1397  
CODEN: JCMIDW; ISSN: 0095-1137  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
TI Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric  
polypeptide for diagnosis of **HCV** infection  
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:231556 CAPLUS  
DOCUMENT NUMBER: 130:251206  
TITLE: Chemiluminescent immunoassay for detecting antibodies  
to **HCV**  
INVENTOR(S): Chien, David Y.; Arcangel, Phillip; Tirell, Stephen;  
Ziegler, Wanda  
PATENT ASSIGNEE(S): Chiron Corporation, USA  
SOURCE: PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915898	A1	19990401	WO 1998-US19693	19980922
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,				
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				
TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2303123	AA	19990401	CA 1998-2303123	19980922
AU 9894979	A1	19990412	AU 1998-94979	19980922
EP 1021719	A1	20000726	EP 1998-948398	19980922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI  
 JP 2001517797 T2 20011009 JP 2000-513145 19980922  
 US 6391540 B1 20020521 US 1998-158301 19980922  
 US 2001039009 A1 20011108 US 2001-775962 20010202  
 US 6537745 B2 20030325  
 US 2003170618 A1 20030911 US 2003-354476 20030128  
 PRIORITY APPLN. INFO.: US 1997-59703P P 19970922  
 US 1998-83921P P 19980501  
 US 1998-158815 A1 19980922  
 WO 1998-US19693 W 19980922  
 US 2001-775962 A1 20010202

TI Chemiluminescent immunoassay for detecting antibodies to **HCV**  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1998:268513 CAPLUS  
 DOCUMENT NUMBER: 128:321945  
 TITLE: Preparation of peptide analogs as inhibitors of serine  
 proteases, particularly hepatitis C virus **NS3**  
 protease  
 INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David  
 D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer,  
 Luc J.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.;  
 Harbeson, Scott L.; Deininger, David D.; Murcko, Mark  
 A.; Bhisetti, Govinda Rao; Farmer, Luc J.  
 SOURCE: PCT Int. Appl., 128 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268391	AA	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 183120	A	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	B	20040107		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				
AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
NO 9901832	A	19990617	NO 1999-1832	19990416

US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 2002032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 2004266731	A1	20041230	US 2003-607716	20030627
PRIORITY APPLN. INFO.:			US 1996-28290P	P 19961018
			EP 1997-946273	A3 19971017
			WO 1997-US18968	W 19971017
			US 1999-293247	A 19990416
			US 2001-875390	A3 20010606

OTHER SOURCE(S): MARPAT 128:321945

TI Preparation of peptide analogs as inhibitors of serine proteases,  
particularly hepatitis C virus **NS3** protease

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:337757 CAPLUS

DOCUMENT NUMBER: 125:51983

TITLE: Synthetic depsipeptide substrates for the assay of  
human hepatitis C virus protease

AUTHOR(S): Bianchi, Elisabetta; Steinkueler, Christian; Taliani,  
Marina; Urbani, Andrea; De Francesco, Raffaele; Pessi,  
Antonello

CORPORATE SOURCE: Istituto Ricerche Biologia Molecolare, P. Angeletti,  
Rome, 00040, Italy

SOURCE: Analytical Biochemistry (1996), 237(2), 239-244  
CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Synthetic depsipeptide substrates for the assay of human hepatitis C virus  
protease

L24 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:119641 CAPLUS

DOCUMENT NUMBER: 124:199915

TITLE: Examination of IgM antibody to hepatitis C virus and  
analysis on hepatitis C patients' sera

AUTHOR(S): Ning, Yang; Zhao, Li; Cheng, Ming; Yang, Junying;  
Chen, Lailin

CORPORATE SOURCE: National Institute of Vaccine and Serum, Beijing,  
100024, Peop. Rep. China

SOURCE: Zhonghua Weishengwuxue He Mianyixue Zazhi (1995),  
15(4), 254-7

CODEN: ZWMZDP; ISSN: 0254-5101

PUBLISHER: Weishenbu Beijing Shengwu Zhipin Yanjiuso

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

TI Examination of IgM antibody to hepatitis C virus and analysis on hepatitis  
C patients' sera

L24 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:915279 CAPLUS

DOCUMENT NUMBER: 124:49963

TITLE: Evaluation of a **HCV** antibody test,  
"IMx-**HCV**" by enzyme immunoassay using  
microparticle

AUTHOR(S): Hayashi, Nobuhide; Nakamura, Isao; Ishii, Yukiko;  
Higashiguchi, Kanae; Mukai, Masahiko; Kumagai,  
Shunichi

CORPORATE SOURCE: Department of Clinical Laboratory, Kobe University  
Hospital, Kobe, Japan

SOURCE: Igaku to Yakugaku (1995), 34(1), 151-61  
CODEN: IGYAEI; ISSN: 0389-3898

PUBLISHER: Shizen Kagakusha

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

TI Evaluation of a **HCV** antibody test, "IMx·**HCV**" by  
enzyme immunoassay using microparticle

L24 ANSWER 26 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2006:30094 BIOSIS  
DOCUMENT NUMBER: PREV200600030662  
TITLE: Highly sensitive FRET substrate for detection of  
**HCV** protease.  
AUTHOR(S): Tong, X. H. [Reprint Author]; Sheng, L.; Zhong, X. F.;  
Tang, Y.; Lu, J.; Diwu, Z. J.; Hong, A.  
CORPORATE SOURCE: AnaSpec Inc, San Jose, CA 95131 USA  
SOURCE: Biopolymers, (2005) Vol. 80, No. 4, pp. 559.  
Meeting Info.: 19th American Peptide Symposium. San Diego,  
CA, USA. June 18 -23, 2005. Amer Peptide Soc; AAPTEC; Amer  
Peptide Co; Amer Hlth/GE Healthcare; Amgen Inc; BACHEM;  
BIOMOL Int; C S Bio Co; Cambridge Res Biochem; Chemico Int  
Inc; Chem Today; Eli Lilly & Co; ESCOM Sci Fdn; Genentech;  
Hoffman-La Roche Inc; Merck Res Lab; Midwest Bio-Tech Inc;  
NeoMPS Inc; New England BioLabs Inc; Novo Nordisk A/S;  
Peptides Int Inc; PharmaChem; PolyPeptide Lab Inc; RSP  
Amino Acide LLC; Senn Chem USA; Sinopep Pharmaceut Inc;  
SynPep Corp; Synthetech Inc; UCB Bioproducts Inc.  
CODEN: BIPMAA. ISSN: 0006-3525.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; (Meeting Poster)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 28 Dec 2005  
Last Updated on STN: 28 Dec 2005

TI Highly sensitive FRET substrate for detection of **HCV** protease.

L24 ANSWER 27 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2004:1907 BIOSIS  
DOCUMENT NUMBER: PREV200400003269  
TITLE: **Solid phase** parallel synthesis of  
alpha-ketoamide inhibitors of NS3cntdot4A **HCV**  
protease.  
AUTHOR(S): Court, John J. [Reprint Author]; Cottrell, Kevin C.  
[Reprint Author]; Harbeson, Scott L. [Reprint Author];  
Pitlik, Janos [Reprint Author]  
CORPORATE SOURCE: Department of Medicinal Chemistry, Vertex Pharmaceuticals  
Inc, 130 Waverly Street, Cambridge, MA, 02139, USA  
john\_court@vrtx.com  
SOURCE: Abstracts of Papers American Chemical Society, (2003) Vol.  
226, No. 1-2, pp. MEDI 97. print.  
Meeting Info.: 226th ACS (American Chemical Society)  
National Meeting. New York, NY, USA. September 07-11, 2003.  
American Chemical Society.  
ISSN: 0065-7727 (ISSN print).  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 17 Dec 2003  
Last Updated on STN: 17 Dec 2003

TI **Solid phase** parallel synthesis of alpha-ketoamide  
inhibitors of NS3cntdot4A **HCV** protease.

L24 ANSWER 28 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2000:70638 BIOSIS  
DOCUMENT NUMBER: PREV200000070638  
TITLE: A loop-mimetic inhibitor of the **HCV-NS3**  
protease derived from a minibody.  
AUTHOR(S): Martin, F.; Steinkuhler, C.; Brunetti, M.; Pessi, A.;  
Cortese, R.; De Francesco, R.; Sollazzo, M. [Reprint  
author]  
CORPORATE SOURCE: Istituto di Ricerche di Biologia Molecolare (IRBM) P.  
Angeletti, Via Pontina Km 30, 600-00040, Pomezia (Roma),

Italy  
SOURCE: Protein Engineering, (Nov., 1999) Vol. 12, No. 11, pp.  
1005-1011. print.  
CODEN: PRENE9. ISSN: 0269-2139.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 16 Feb 2000  
Last Updated on STN: 3 Jan 2002  
TI A loop-mimetic inhibitor of the **HCV-NS3** protease  
derived from a minibody.

L24 ANSWER 29 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1999:241608 BIOSIS  
DOCUMENT NUMBER: PREV199900241608  
TITLE: Use of a novel hepatitis C virus (**HCV**)  
major-epitope chimeric polypeptide for diagnosis of  
**HCV** infection.  
AUTHOR(S): Chien, David Y. [Reprint author]; Arcangel, Phillip;  
Medina-Selby, Angelica; Coit, Doris; Baumeister, Mark;  
Nguyen, Steve; George-Nascimento, Carlos; Gyenes,  
Alexander; Kuo, George; Valenzuela, Pablo  
CORPORATE SOURCE: Life Science Center 4.302, Chiron Corporation, 4560 Horton  
St., Emeryville, CA, 94507, USA  
SOURCE: Journal of Clinical Microbiology, (May, 1999) Vol. 37, No.  
5, pp. 1393-1397. print.  
CODEN: JCMIDW. ISSN: 0095-1137.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 17 Jun 1999  
Last Updated on STN: 17 Jun 1999  
TI Use of a novel hepatitis C virus (**HCV**) major-epitope chimeric  
polypeptide for diagnosis of **HCV** infection.

L24 ANSWER 30 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1996:334219 BIOSIS  
DOCUMENT NUMBER: PREV199699056575  
TITLE: Synthetic depsipeptide substrates for the assay of human  
hepatitis C virus protease.  
AUTHOR(S): Bianchi, Elisabetta; Steinkuehler, Christian; Taliani,  
Marina; Urbani, Andrea; De Francesco, Raffaele; Pessi,  
Antonello [Reprint author]  
CORPORATE SOURCE: Istituto di Ricerche di Biologia Molecolare P. Angeletti,  
Via Pontina Km 30,600, 00040 Pomezia, Rome, Italy  
SOURCE: Analytical Biochemistry, (1996) Vol. 237, No. 2, pp.  
239-244.  
CODEN: ANBCA2. ISSN: 0003-2697.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 26 Jul 1996  
Last Updated on STN: 27 Jul 1996  
TI Synthetic depsipeptide substrates for the assay of human hepatitis C virus  
protease.

L24 ANSWER 31 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1996:221512 BIOSIS  
DOCUMENT NUMBER: PREV199698777641  
TITLE: IgM antibody response to hepatitis C virus in end-stage  
renal disease.  
AUTHOR(S): Fabrizi, F. [Reprint author]; Lunghi, G.; Guarnori, I.;  
Raffaele, L.; Erba, G.; Pagano, A.; Locatelli, F.  
CORPORATE SOURCE: Nephrol. Dep., Hosp. of Lecco, via Ghislanzoni 22, 22053  
Lecco, Italy  
SOURCE: Nephrology Dialysis Transplantation, (1996) Vol. 11, No. 2,  
pp. 314-318.  
ISSN: 0931-0509.  
DOCUMENT TYPE: Article

LANGUAGE: English  
ENTRY DATE: Entered STN: 8 May 1996  
Last Updated on STN: 8 May 1996  
TI IgM antibody response to hepatitis C virus in end-stage renal disease.

L24 ANSWER 32 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1995:486794 BIOSIS  
DOCUMENT NUMBER: PREV199598501094  
TITLE: Examination of IgM antibody to hepatitis C and analysis on hepatitis C patients' sera.  
AUTHOR(S): Ning, Yang; Zhao; Li; Cheng; Ming  
CORPORATE SOURCE: National Vaccine Serum Inst., Beijing 100024, China  
SOURCE: Zhonghua Weishengqixue He Mianyixue Zazhi, (1995) Vol. 15, No. 4, pp. 254-257.  
CODEN: ZWMZDP. ISSN: 0254-5101.  
DOCUMENT TYPE: Article  
LANGUAGE: Chinese  
ENTRY DATE: Entered STN: 9 Nov 1995  
Last Updated on STN: 9 Nov 1995

TI Examination of IgM antibody to hepatitis C and analysis on hepatitis C patients' sera.

L24 ANSWER 33 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1993:367187 BIOSIS  
DOCUMENT NUMBER: PREV199396052862  
TITLE: Evaluation of three recombinant antigens for detection of antibodies to hepatitis C virus.  
AUTHOR(S): Cheng, Da-Rong  
CORPORATE SOURCE: Natl. Vaccine Serum Inst., Beijing, China  
SOURCE: Chinese Journal of Microbiology and Immunology (Beijing), (1993) Vol. 13, No. 2, pp. 97-100.  
DOCUMENT TYPE: Article  
LANGUAGE: Chinese  
ENTRY DATE: Entered STN: 6 Aug 1993  
Last Updated on STN: 6 Aug 1993

TI Evaluation of three recombinant antigens for detection of antibodies to hepatitis C virus.

L24 ANSWER 34 OF 34 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1993:187917 BIOSIS  
DOCUMENT NUMBER: PREV199395098367  
TITLE: Synthesis and antigenic activity of the peptides from the core and NS3 proteins of the hepatitis C virus.  
AUTHOR(S): Semiletov, Yu. A.; Firsova, T. V.; Shibnev, V. A.; Vyazov, S. O.  
CORPORATE SOURCE: D.I. Ivanovskii Inst. Virol., Acad. Med. Sci. Russ., Moscow, Russia  
SOURCE: Bioorganicheskaya Khimiya, (1993) Vol. 19, No. 1, pp. 126-129.  
CODEN: BIKHD7. ISSN: 0132-3423.  
DOCUMENT TYPE: Article  
LANGUAGE: Russian  
ENTRY DATE: Entered STN: 9 Apr 1993  
Last Updated on STN: 9 Apr 1993

TI Synthesis and antigenic activity of the peptides from the core and NS3 proteins of the hepatitis C virus.